http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
Natsume Shigeyoshi,Sang-bong Yoon 실천경영학회 2011 실천경영연구 Vol.6 No.1
Japan and Korea become to introduce global IFRS at similar time, but different appraoches have resulted in different progress and anticipation. While Korean road map was so far nearly accomplished under the adoption way, Japanese road map is now facing various issues to be solved. It will be up to the business circumstances how the full adoption of IFRS would progress in each country.
夏目重美(Shigeyoshi, Natsume) 실천경영학회 2006 실천경영연구 Vol.1 No.1
On June 29, 2005, the 162th Diet passed a company law that addresses issues related to regulation, enforcement, accounting, and electronic notification, to name a few. The law went into effect on May 1, 2006. This thesis describes the establishment of this law and requirements with respect to the acquisition of limited (Ltd.) status; corporate organizational design; accounting procedures; corporate reorganization; the Japanese versions of LLC and LLP, respectively; and the potential for management innovation vis-à-vis Japanese enterprises. The law, at the very least, appears to be a compass that points to a route that can lead to genuine management reformation in Japanese enterprises; however, it is necessary to observe how the system operates in reality in order to gauge the law’s degree of success or failure.
Suzuki, Aya,Nobusawa, Sumihito,Natsume, Atsushi,Suzuki, Hiromichi,Kim, Young-Ho,Yokoo, Hideaki,Nagaishi, Masaya,Ikota, Hayato,Nakazawa, Takuro,Wakabayashi, Toshihiko,Ohgaki, Hiroko,Nakazato, Yoichi M. Nijhoff ; Kluwer Academic Publishers 2014 Journal of neuro-oncology Vol.120 No.2
<P>Diagnosis of low-grade diffuse gliomas based on morphology is highly subjective and, therefore, is often difficult, with significant intra- and interobserver variability. Here, we investigated WHO grade II diffuse astrocytomas, oligoastrocytomas and oligodendrogliomas for immunohistochemical expression of Olig2, measuring its labeling index (LI), and evaluated the significance of Olig2 LI in the histological and molecular classifications. The means of Olig2 LI in glioma cells were 43.7 % in diffuse astrocytomas, 59.3 % in oligoastrocytomas and 76.1 % in oligodendrogliomas. There was a statistically significant difference between all pairs of histological types. The mean of Olig2 LI of gliomas with 1p/19q loss ± IDH1/2 mutation, the majority of them being oligodendrogliomas, was significantly higher than the means of those with TP53 mutation ± IDH1/2 mutation and IDH1/2 mutation only, the majority of which were diffuse astrocytomas (70.1 vs. 47.2 and 46.5 %, respectively). When categorized according to the classification of Jiao et al., Olig2 LI of I-CF gliomas (cases with IDH and one or more of CIC, FUBP1 or combined 1p/19q loss; mean 71.0 %) was significantly higher than that of I-A gliomas (cases with IDH and ATRX alterations; mean 45.3 %). These molecular classifications were reported to correlate well with clinical outcome. However, borderlines of Olig2 LI were broad and could not clearly distinguish genotypes in the molecular classifications. In conclusion, Olig2 LI cannot be taken as a complete surrogate marker for molecular genotype, but could possibly provide some ancillary information when molecular assay is not availabe.</P>
Aina Kunitomo,Kazunari Misawa,Yuichi Ito,Seiji Ito,Eiji Higaki,Seiji Natsume,Takashi Kinoshita,Tetsuya Abe,Koji Komori,Yasuhiro Shimizu 대한위암학회 2021 Journal of gastric cancer Vol.21 No.4
Purpose: Type 4 gastric cancer (GC) has a very poor prognosis even after curative resection, and the survival benefit of splenectomy for splenic hilar lymph node (LN; #10) dissection in type 4 GC remains equivocal. This study aimed to clarify the clinical significance of splenectomy for #10 dissection in patients with type 4 GC. Materials and Methods: The data of a total of 56 patients with type 4 GC who underwent total gastrectomy with splenectomy were retrospectively analyzed. Postoperative morbidity, state of LN metastasis, survival outcomes, and therapeutic value index (TVI) of each LN station were evaluated. TVI was calculated by multiplying the incidence of LN metastasis at each nodal station and the 5-year overall survival (OS) of patients who had metastasis to each node. Results: Overall, the postoperative morbidity rate was 28.6%, and the incidence of #10 metastasis in the patients was 28.6%. The 5-year OS rate for all patients was 29.9%, and most patients developed peritoneal recurrence. Moreover, the 5-year OS rates with and without #10 metastasis were 6.7% and 39.1% (median survival time, 20.4 vs. 46.0 months; P=0.006). The TVI of #10 was as low as 1.92. Conclusions: The clinical significance of splenectomy in the dissection of #10 for type 4 GC is limited and splenectomy for splenic hilar dissection alone should be omitted.